Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Hero

Showing results (31-40 of 141) with videos related to

Pageof 15
Sort By:
Pediatric Blood & Cancer|September 23, 2016
Lack of immunocytological GD2 expression on neuroblastoma cells in bone marrow at diagnosis, during treatment, and at recurrenceRoswitha Schumacher-Kuckelkorn, Ruth Volland, Anke Gradehandt, et al.
BMC Cancer|January 20, 2011
Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapyThorsten Simon, Barbara Hero, Andreas Faldum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2004
Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastomaThorsten Simon, Barbara Hero, Andreas Faldum, et al.
Journal of Pediatric Surgery|October 13, 2017
Retrospective analysis of relapsed abdominal high-risk neuroblastomaMartin Dübbers, Thorsten Simon, Frank Berthold, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|June 1, 2005
Esthesioneuroblastoma in childhood and adolescence. Better prognosis with multimodal treatment?Hans Theodor Eich, Rolf-Peter Müller, Oliver Micke, et al.
Medical and Pediatric Oncology|September 5, 2002
Long-term survival of children with neuroblastoma prior to the neuroblastoma screening project in GermanyTatjana Burkhardt-Hammer, Claudia Spix, Hermann Brenner, et al.
British Journal of Cancer|September 26, 2019
Correction: Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidationFrank Berthold, Angela Ernst, Barbara Hero, et al.
Frontiers in Pediatrics|May 8, 2026
Status Quo analysis of an exercise therapy care model in pediatric oncology during acute therapy: perspectives from patients, parents, siblings, and staffLena Böhlke, Thorsten Simon, Barbara Hero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
Repp86 expression and outcome in patients with neuroblastomaMatthias Krams, Hans-Juergen Heidebrecht, Barbara Hero, et al.
British Journal of Cancer|July 12, 2018
Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidationFrank Berthold, Angela Ernst, Barbara Hero, et al.
Pageof 15

Showing results (31-40 of 141) with videos related to

Sort By:
Pageof 15
Pediatric Blood & Cancer|September 23, 2016
Lack of immunocytological GD2 expression on neuroblastoma cells in bone marrow at diagnosis, during treatment, and at recurrenceRoswitha Schumacher-Kuckelkorn, Ruth Volland, Anke Gradehandt, et al.
BMC Cancer|January 20, 2011
Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapyThorsten Simon, Barbara Hero, Andreas Faldum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2004
Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastomaThorsten Simon, Barbara Hero, Andreas Faldum, et al.
Journal of Pediatric Surgery|October 13, 2017
Retrospective analysis of relapsed abdominal high-risk neuroblastomaMartin Dübbers, Thorsten Simon, Frank Berthold, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|June 1, 2005
Esthesioneuroblastoma in childhood and adolescence. Better prognosis with multimodal treatment?Hans Theodor Eich, Rolf-Peter Müller, Oliver Micke, et al.
Medical and Pediatric Oncology|September 5, 2002
Long-term survival of children with neuroblastoma prior to the neuroblastoma screening project in GermanyTatjana Burkhardt-Hammer, Claudia Spix, Hermann Brenner, et al.
British Journal of Cancer|September 26, 2019
Correction: Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidationFrank Berthold, Angela Ernst, Barbara Hero, et al.
Frontiers in Pediatrics|May 8, 2026
Status Quo analysis of an exercise therapy care model in pediatric oncology during acute therapy: perspectives from patients, parents, siblings, and staffLena Böhlke, Thorsten Simon, Barbara Hero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
Repp86 expression and outcome in patients with neuroblastomaMatthias Krams, Hans-Juergen Heidebrecht, Barbara Hero, et al.
British Journal of Cancer|July 12, 2018
Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidationFrank Berthold, Angela Ernst, Barbara Hero, et al.
Pageof 15